Watchlist

Watchlist
Anika Therapeutics Inc. (ANIK)
Anika Therapeutics Inc. (ANIK)
Your Daily Pharma Scoop: Loxo Data, GW Pharmaceuticals' Q4 Results, Zynerba Positive Data
This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Total Pharma Tracker subscribers get the full version with actionable ideas one …
Flexion - When Approvals Go Bad
Welcome back. We're here to give you a fresh look at the now cratering post-approval on Flexion ( FLXN ). You can read our original bullish piece here . Our original price targets, which hovered around the $35-45 range, were dependent on Flexion getting into the market and being viewed as…
Your Daily Pharma Scoop: Celgene's Big Fall, Tesaro VARUBI Approval, TGTX Midstage Success
This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Analysis of top Seeking Alpha coverage: Celgene It has been a disas…
Anika Therapeutics' (ANIK) CEO Charles Sherwood on Q3 2017 Results - Earnings Call Transcript
Anika Therapeutics Inc. (ANIK) Q3 2017 Earnings Conference Call October 26, 2017 9:00 AM ET Executives Charles Sherwood - Chief Executive Officer Sylvia Cheung - Chief Financial Officer Analysts Joe Munda - First Analysis Securities Mike Petusky - Barrington Research Assoc…
Anika Therapeutics Inc. 2017 Q3 - Results - Earnings Call Slides
The following slide deck was published by Anika Therapeutics Inc. in conjunction with their 2017 Q3 earnings Read more …
Anika Therapeutics misses by $0.01, misses on revenue
Anika Therapeutics (NASDAQ: ANIK ): Q3 EPS of $0.46 misses by $0.01 . Revenue of $27.2M (+5.5% Y/Y) misses by $1.72M . Press Release More news on: Anika Therapeutics Inc., Earnings news and commentary, Healthcare stocks news,
Anika Reports Third Quarter 2017 Financial Results
Completed Enrollment in CINGAL Phase III Clinical Trial; Advancement of Regenerative Medicine Pipeline; MONOVISC Revenue Increased 50% Year-over-Year Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based …
Anika Completes Enrollment in Second Pivotal Phase III Trial of CINGAL for the Treatment of Knee Pain Associated with Osteoarthritis
Anika Therapeutics, Inc . (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced the completion of enrollment in its second pivotal Phase III trial evaluating CINGAL &#xA…
Your Daily Pharma Scoop: Soliris New Indication, Gilead's NASH Data, What Keeps Synergy Down?
This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service . Analysis of top Seeking Alpha coverage: Synergy Today we will discuss an article on Synerg…
Notable earnings after Wednesday's close
ABX , ACGL , AEM , AFL , AGNC , AHL , ALGT , AMGN , AMSF , ANIK , ASGN , AXS , AXTI , BGG , BLKB , BOFI , BPI , BWLD , CA , CATY , CDE , CLGX , CMO , CNO , CSGP , CSII , CSLT , CSV , CTXS , CUBI , CUZ , CW , CYS , DLB , DLR , DRE , ECHO , ELY , ESND , …
Anika Announces the Forthcoming Appointment of Thomas M. Finnerty as Chief Human Resources Officer
Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced the appointment of Thomas M. Finnerty as its Chief Human Resources Officer. Mr. Finnerty br…
Anika Therapeutics Inc. (ANIK)